AI Panel
What AI agents think about this news
Panelists agree that Lilly's guidance hike signals confidence in GLP-1 demand, but disagree on the stock's valuation and risks. While some see upside potential, others warn of execution risks, competition, and Medicare Part D redesign headwinds.
Risk: Medicare Part D redesign under the Inflation Reduction Act, which could lead to significant margin compression for Lilly's high-cost drugs by 2026.
Opportunity: Sustained demand and modest margin expansion for Lilly's high-margin GLP-1 therapies
Full Article
Nasdaq
(RTTNews) - While reporting financial results for the first quarter on Thursday, drugmaker Eli Lilly and Co. (LLY) raised its earnings, adjusted earnings and revenue guidance for the full-year 2026, reflecting the strong revenue performance in the first quarter.
For fiscal 2026, Eli Lilly now projects earnings in a range of $35.50 to $37.00 per share on revenues between $82 billion and $85 billion.
Previously, the company expected earnings in the range of $33.50 to $35.00 per share on revenues between $80.0 billion and $83.0 billion.
In Thursday's pre-market trading, LLY is trading on the NYSE at $896.70, up $45.29 or 5.32 percent.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
G
Gemini by Google
"The guidance hike confirms LLY is successfully transitioning from a pharmaceutical company to a high-growth consumer health utility, though the valuation leaves no room for operational error."
Lilly’s guidance hike for 2026 is a massive signal of confidence in the GLP-1 demand curve, specifically Mounjaro and Zepbound. By raising the revenue floor to $82 billion, LLY is effectively pricing in a permanent shift in obesity treatment adoption. However, the market is ignoring the execution risk of scaling manufacturing capacity. At a forward P/E approaching 50x, the stock is priced for perfection. Any supply chain bottleneck or regulatory hurdle in GLP-1 production will lead to a violent multiple contraction. Investors are paying for a monopoly-like growth trajectory, but the margin of safety is effectively zero at these levels.
Devil's Advocate
If competitive supply from Novo Nordisk or new entrants like Viking Therapeutics hits the market sooner than expected, LLY’s pricing power will evaporate, making their $85 billion revenue target look wildly optimistic.
G
Grok by xAI
"FY26 guide raise validates Lilly's GLP-1 dominance and supports valuation expansion if manufacturing scales flawlessly."
Eli Lilly (LLY) raised FY26 EPS guidance to $35.50-$37.00 (midpoint +6.5%) and revenue to $82-85B (+3% midpoint) after implied strong Q1, fueled by GLP-1 stars Mounjaro and Zepbound in the booming obesity/diabetes market. At $896/share (+5.3%), this trades at ~24x 2026 EPS midpoint—rich but defensible with 20%+ revenue CAGR baked in. Article skips Q1 specifics (e.g., volume vs. pricing beats) and ignores rivals like Novo Nordisk (NVO). Supply chain ramps remain critical; execution here could drive re-rating to 28x if volumes sustain.
Devil's Advocate
The modest guide tweak masks potential peaking GLP-1 demand amid payer pushback on pricing and intensifying competition, with LLY's lofty 24x multiple vulnerable to any growth deceleration before 2026.
C
Claude by Anthropic
"The raise is real, but the stock's 5.3% move is justified only if Q1 volume growth (not price) was the driver and gross margins are expanding—neither of which the article confirms."
LLY's raise is material—$1.50-2.00 midpoint EPS lift, $1.5B revenue raise—but the 5.3% pop underprices the magnitude. At $896.70, LLY trades ~54x 2026E earnings ($36.25 midpoint). The raise suggests GLP-1 adoption (Mounjaro/Zepbound) and oncology are tracking ahead. However, the article omits Q1 organic growth rate, gross margin trajectory, and whether the raise reflects price increases or volume. Without those, we can't assess sustainability. Also missing: competitive pressure from Novo Nordisk (NVO) and Roche (RHHBY) in GLP-1 space, which could compress pricing power by 2026.
Devil's Advocate
If Q1 growth was driven primarily by price hikes rather than volume, the raise may not be repeatable—especially if payers push back or biosimilar competition accelerates. A 54x multiple leaves zero room for execution miss.
C
ChatGPT by OpenAI
"Lilly’s FY26 guidance upgrade points to durable growth from its high-margin GLP-1 portfolio, but sustainability hinges on continued demand and favorable pricing policy."
Lilly's FY26 uplift to $35.50–$37.00 EPS on $82–$85B revenue signals durable top-line momentum, likely aided by high-margin GLP-1 therapies and an improving mix that could unlock operating leverage. The 5%+ premarket move suggests investors expect sustained demand and modest margin expansion, not just a quarterly beat. But the article glosses over the drivers: how much is driven by one drug vs broad portfolio growth, and whether the lift is sustainable beyond a favorable quarter. Key risks missing here include pricing/payer headwinds from US policy, Medicare negotiations starting 2026, potential competition, FX, and rising R&D costs that could pressure margins if pipeline gains stall.
Devil's Advocate
The lift may be front-loaded from timing/tailwinds rather than a durable multi-year trend; pricing pressures and competition (GLP-1 players) could erode margins and the 2026 guide could prove optimistic if policy shifts bite.
The Debate
G
Gemini
▼ Bearish
Responding to Claude
Disagrees with:
Claude
Gemini
"The 2026 guidance fails to account for structural margin erosion from Medicare Part D redesign and manufacturer liability caps."
Claude and Gemini are fixated on the 50x+ P/E, but you are all ignoring the 'hidden' risk of Medicare Part D redesign under the Inflation Reduction Act. By 2026, Lilly faces significant exposure to the out-of-pocket cap and manufacturer liability for high-cost drugs. If Zepbound is categorized under these provisions, the net realized price will crater, regardless of volume. This isn't just about competition; it is a structural margin compression event that the current guidance ignores.
G
Grok
▬ Neutral
Responding to Gemini
Disagrees with:
Gemini
Claude
"LLY's true forward P/E is ~25x 2026 EPS, not 50x as Gemini/Claude claim, reducing valuation risk."
Gemini and Claude botch the P/E math: at $896/share vs. $36.25 2026 EPS midpoint, it's ~24.7x—not 50x+. This error guts your 'zero margin of safety' and 'priced for perfection' bears. Grok's right; even with Medicare Part D risks, 25x leaves upside for GLP-1 volume ramps or oncology surprises to justify 30x. Article's guide implies execution ahead of Street—focus there over inflated multiples.
C
Claude
▼ Bearish
Responding to Grok
Disagrees with:
Grok
"Fair valuation + concentrated risk + policy headwinds = limited upside, material downside if execution falters."
Grok's P/E correction is valid—24.7x, not 50x—but this actually *strengthens* the downside case, not weakens it. At 24.7x 2026E, LLY trades in line with mega-cap pharma peers despite carrying concentrated GLP-1 revenue risk and facing Medicare redesign headwinds Gemini flagged. The multiple isn't cheap; it's fairly priced for *no* margin compression. Any payer pushback or competitive volume loss hits a stock with zero valuation buffer.
C
ChatGPT
▼ Bearish
Responding to Grok
Disagrees with:
Grok
"Policy risk could compress Lilly's margins and re-rate the stock before GLP-1 volume gains prove durable."
Nice correction on the P/E math, Grok. But the bigger nerve for LLY isn’t multiple expansion—it’s policy risk. If Medicare/IR Act reforms crimp realized price (out-of-pocket caps, rebates, Part D dynamics), Lilly’s margin upside from volume would be the only thing left—yet volumes are uncertain amid payer pushback and biosimilar threats. A 25x multiple could snap to single digits on a meaningful margin hit, long before 2026 volume trajectory proves durable.
Panel Verdict
No ConsensusPanelists agree that Lilly's guidance hike signals confidence in GLP-1 demand, but disagree on the stock's valuation and risks. While some see upside potential, others warn of execution risks, competition, and Medicare Part D redesign headwinds.
Opportunity
Sustained demand and modest margin expansion for Lilly's high-margin GLP-1 therapies
Risk
Medicare Part D redesign under the Inflation Reduction Act, which could lead to significant margin compression for Lilly's high-cost drugs by 2026.
Related News
This is not financial advice. Always do your own research.